Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange about Scruitinizer report and voting result in pdf form.
BIOFILCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biofil Chemicals & Pharmaceuticals Limited filed the voting results and scrutinizer's report for its 40th Annual General Meeting held on September 27, 2025 via video conferencing. All 8 resolutions were approved by shareholders with overwhelming majority, with each resolution receiving over 99.98% support. Key resolutions included adoption of FY25 audited financial statements, re-appointment of Mr. Meet Shah as director, appointment of Joshi Sahay & Company as secretarial auditor, re-appointment of two independent directors (Mr. Ashok Kumar Ramawat and Mr. Satish Beohar) for a second five-year term, approval of material related party transactions with Cyano Pharma Private Limited (with promoter group votes excluded as invalid), change in designation of Mr. Ketan Shah from Whole Time Director to Chairman and Managing Director, and confirmation of Mr. Smitesh Shah as Promoter Non-Executive Non-Independent Director. Voting turnout was about 52% with 8,469,916 votes polled out of 16,273,800 outstanding shares from a total shareholder base of 25,641 as of the record date of September 20, 2025. The scrutinizer was L.N. Joshi, Practicing Company Secretary.
This is a routine procedural filing confirming smooth completion of the AGM with strong shareholder backing on all resolutions, including key board changes and related party transactions. No material negative signal for the stock; the elevation of Mr. Ketan Shah to Chairman and Managing Director and approval of related party deals with Cyano Pharma are noteworthy governance updates investors should track.